{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:06:40Z","timestamp":1776456400277,"version":"3.51.2"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13318-024-00916-1","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T03:39:52Z","timestamp":1726285192000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Whole Body Physiologically\u00a0Based Pharmacokinetic Model to Explain A Patient With Drug\u2013Drug Interaction Between Voriconazole and Flucloxacillin"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-2383","authenticated-orcid":false,"given":"Heshu","family":"Abdullah-Koolmees","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia F.","family":"van den Nieuwendijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone M. K. ten","family":"Hoope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda G. W.","family":"Franken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medhat M.","family":"Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten R.","family":"Seefat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora L.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Harry","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-3407","authenticated-orcid":false,"given":"Imke H.","family":"Bartelink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"issue":"6","key":"916_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3389\/fmicb.2015.00669","volume":"3","author":"MM Azevedo","year":"2015","unstructured":"Azevedo MM, Teixeira-Santos R, Silva AP, Cruz L, Ricardo E, Pina-Vaz C, Rodrigues AG. The effect of antibacterial and non-antibacterial compounds alone or associated with antifugals upon fungi. Front Microbiol. 2015;3(6):669. https:\/\/doi.org\/10.3389\/fmicb.2015.00669.","journal-title":"Front Microbiol"},{"key":"916_CR2","unstructured":"Voriconazole: National Library of Medicine. MedlinePlus [Internet]. Medlineplus.gov. [cited 2024 Aug 12]. Available from: https:\/\/medlineplus.gov\/"},{"key":"916_CR3","unstructured":"Flucloxacillin 500mg Capsules - Summary of Product Characteristics (SmPC) - Homepage [Internet]. European Medicines Agency (EMA). [cited 2024 Aug 12]. Available from: https:\/\/www.ema.europa.eu\/en\/homepage"},{"issue":"7","key":"916_CR4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/jac\/dkv069","volume":"70","author":"B Kennedy","year":"2015","unstructured":"Kennedy B, Larcombe R, Chaptini C, Gordon DL. Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection. J Antimicrob Chemother. 2015;70(7):2171\u20133. https:\/\/doi.org\/10.1093\/jac\/dkv069.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"916_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/antibiotics10091112","volume":"10","author":"R Van Daele","year":"2021","unstructured":"Van Daele R, Wauters J, De Cock P, Buyle F, Leys J, Van Brantegem P, et al. Concomitant treatment with voriconazole and flucloxacillin: a combination to avoid. Antibiotics (Basel). 2021;10(9):1112. https:\/\/doi.org\/10.3390\/antibiotics10091112.","journal-title":"Antibiotics (Basel)."},{"key":"916_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00915-17","author":"EW Muilwijk","year":"2017","unstructured":"Muilwijk EW, Dekkers BGJ, Henriet SSV, Verweij PE, Witjes B, Lashof AMLO, et al. Flucloxacillin results in suboptimal plasma voriconazole concentrations. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00915-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"916_CR7","doi-asserted-by":"publisher","first-page":"446.e1","DOI":"10.1016\/j.cmi.2021.06.039","volume":"28","author":"E Wallenburg","year":"2022","unstructured":"Wallenburg E, Br\u00fcggemann RJM, Roberts JA, Jager NGL, Ulldemolins M, Wilkes S, et al. A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients. Clin Microbiol Infect. 2022;28(3):446.e1-446.e7. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.039.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"916_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/antibiotics9060309","volume":"9","author":"M Stolte","year":"2020","unstructured":"Stolte M, Ali W, J\u00e4nis J, Gessner A, El-Najjar N. Paclitaxel, imatinib and 5-fluorouracil increase the unbound fraction of flucloxacillin in vitro. Antibiotics (Basel). 2020;9(6):309. https:\/\/doi.org\/10.3390\/antibiotics9060309.","journal-title":"Antibiotics (Basel)."},{"issue":"12","key":"916_CR9","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1128\/aac.00951-13","volume":"57","author":"G Wong","year":"2013","unstructured":"Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, et al. Protein binding of \u03b2-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57(12):6165\u201370. https:\/\/doi.org\/10.1128\/aac.00951-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"916_CR10","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.1128\/aac.03641-14","volume":"58","author":"K Vanstraelen","year":"2014","unstructured":"Vanstraelen K, Wauters J, Vercammen I, de Loor H, Maertens J, Lagrou K, et al. Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients. Antimicrob Agents Chemother. 2014;58(11):6782\u20139. https:\/\/doi.org\/10.1128\/aac.03641-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"916_CR11","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/jps.24064","volume":"103","author":"K Vanstraelen","year":"2014","unstructured":"Vanstraelen K, Wauters J, De Loor H, Vercammen I, Annaert P, Lagrou K, et al. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci. 2014;103(8):2565\u201370. https:\/\/doi.org\/10.1002\/jps.24064.","journal-title":"J Pharm Sci"},{"key":"916_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00505","author":"Z-Q-Y Yuan","year":"2020","unstructured":"Yuan Z-Q-Y, Qiao C, Yang Z-C, Yu L, Sun L-N, Qian Y, et al. The impact of plasma protein binding characteristics and unbound concentration of voriconazole on its adverse drug reactions. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00505.","journal-title":"Front Pharmacol"},{"issue":"3","key":"916_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ijantimicag.2018.11.018","volume":"53","author":"S Wilkes","year":"2019","unstructured":"Wilkes S, van Berlo I, ten Oever J, Jansman F, ter Heine R. Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen. Int J Antimicrob Agents. 2019;53(3):310\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.018.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"916_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/10408347.2018.1468728","volume":"49","author":"MN de Menezes","year":"2019","unstructured":"de Menezes MN, de Marco BA, Fiorentino FAM, Zimmermann A, Kogawa AC, Salgado HRN. Flucloxacillin: a review of characteristics, properties and analytical methods. Crit Rev Anal Chem. 2019;49(1):67\u201377. https:\/\/doi.org\/10.1080\/10408347.2018.1468728.","journal-title":"Crit Rev Anal Chem"},{"issue":"3","key":"916_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1067\/mcp.2002.121829","volume":"71","author":"LZ Benet","year":"2002","unstructured":"Benet LZ, Hoener B-A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115\u201321. https:\/\/doi.org\/10.1067\/mcp.2002.121829.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"916_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nrd3287","volume":"9","author":"DA Smith","year":"2010","unstructured":"Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929\u201339. https:\/\/doi.org\/10.1038\/nrd3287.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"916_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cpt.2959","volume":"114","author":"DB Iversen","year":"2023","unstructured":"Iversen DB, Dunvald A-CD, Jespersen DM, Nielsen F, Br\u00f8sen K, Damkier P, et al. Flucloxacillin is a weak inducer of CYP3A4 in healthy adults and 3D spheroid of primary human hepatocytes. Clin Pharmacol Ther. 2023;114(2):434\u201345. https:\/\/doi.org\/10.1002\/cpt.2959.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"916_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106711","volume":"61","author":"A Veringa","year":"2023","unstructured":"Veringa A, Br\u00fcggemann RJ, Span LFR, Biemond BJ, de Boer MGJ, van den Heuvel ER, et al. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial. Int J Antimicrob Agents. 2023;61(2): 106711. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106711.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"916_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/10600280211047864","volume":"56","author":"CM White","year":"2022","unstructured":"White CM. Inflammation suppresses patients\u2019 ability to metabolize cytochrome P450 substrate drugs. Ann Pharmacother. 2022;56(7):809\u201319. https:\/\/doi.org\/10.1177\/10600280211047864.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"916_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40262-022-01173-8","volume":"61","author":"M Gatti","year":"2022","unstructured":"Gatti M, Pea F. The cytokine release syndrome and\/or the proinflammatory cytokines as underlying mechanisms of downregulation of drug metabolism and drug transport: a systematic review of the clinical pharmacokinetics of victim drugs of this drug\u2013disease interaction under different clinical conditions. Clin Pharmacokinet. 2022;61(11):1519\u201344. https:\/\/doi.org\/10.1007\/s40262-022-01173-8.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"916_CR21","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1128\/aac.03820-14","volume":"58","author":"MJP van Wanrooy","year":"2014","unstructured":"van Wanrooy MJP, Span LFR, Rodgers MGG, van den Heuvel ER, Uges DRA, van der Werf TS, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58(12):7098\u2013101. https:\/\/doi.org\/10.1128\/aac.03820-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"916_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/2047-783x-16-4-139","volume":"16","author":"M Sandherr","year":"2011","unstructured":"Sandherr M, Maschmeyer G. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature. Eur J Med Res. 2011;16(4):139. https:\/\/doi.org\/10.1186\/2047-783x-16-4-139.","journal-title":"Eur J Med Res"},{"issue":"7","key":"916_CR23","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1128\/AAC.01671-10","volume":"55","author":"A Lignell","year":"2011","unstructured":"Lignell A, L\u00f6wdin E, Cars O, Chryssanthou E, Sj\u00f6lin J. Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob Agents Chemother. 2011;55(7):3099\u2013104. https:\/\/doi.org\/10.1128\/AAC.01671-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"916_CR24","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/jac\/dkaa187","volume":"75","author":"NGL Jager","year":"2020","unstructured":"Jager NGL, van Hest RM, Xie J, Wong G, Ulldemolins M, Br\u00fcggemann RJM, et al. Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. J Antimicrob Chemother. 2020;75(9):2641\u20139. https:\/\/doi.org\/10.1093\/jac\/dkaa187.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"916_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2013.41","volume":"2","author":"HM Jones","year":"2013","unstructured":"Jones HM, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013;2(8):1\u201312. https:\/\/doi.org\/10.1038\/psp.2013.41.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"916_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2016.11.025","volume":"49","author":"F Qi","year":"2017","unstructured":"Qi F, Zhu L, Li N, Ge T, Xu G, Liao S. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2017;49(4):403\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.025.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"916_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/psp4.12343","volume":"7","author":"N Hanke","year":"2018","unstructured":"Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, et al. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. CPT Pharmacometrics Syst Pharmacol. 2018;7(10):647\u201359. https:\/\/doi.org\/10.1002\/psp4.12343.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"916_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jac\/dkw349","volume":"72","author":"A Veringa","year":"2017","unstructured":"Veringa A, ter Avest M, Span LFR, van den Heuvel ER, Touw DJ, Zijlstra JG, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72(1):261\u20137. https:\/\/doi.org\/10.1093\/jac\/dkw349.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"916_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/psp4.12467","volume":"8","author":"A Elmokadem","year":"2019","unstructured":"Elmokadem A, Riggs MM, Baron KT. Quantitative systems pharmacologyandphysiologically-based pharmacokineticmodeling with mrgsolve: a hands-on tutorial. CPT Pharmacometrics Syst Pharmacol. 2019;8(12):883\u201393. https:\/\/doi.org\/10.1002\/psp4.12467.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"916_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","volume":"80","author":"L Chen","year":"2020","unstructured":"Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Br\u00fcggemann RJM. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020;80(7):671\u201395. https:\/\/doi.org\/10.1007\/s40265-020-01306-y.","journal-title":"Drugs"},{"issue":"106049","key":"916_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106049","volume":"168","author":"D Pe\u00f1a-Lorenzo","year":"2022","unstructured":"Pe\u00f1a-Lorenzo D, Rebollo N, S\u00e1nchez-Hern\u00e1ndez JG, Zarzuelo-Casta\u00f1eda A, V\u00e1zquez-L\u00f3pez L, Otero MJ, et al. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients. Eur J Pharm Sci. 2022;168(106049): 106049. https:\/\/doi.org\/10.1016\/j.ejps.2021.106049.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"916_CR32","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238\u201357. https:\/\/doi.org\/10.1002\/jps.20502.","journal-title":"J Pharm Sci"},{"issue":"6","key":"916_CR33","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259\u201376. https:\/\/doi.org\/10.1002\/jps.20322.","journal-title":"J Pharm Sci"},{"issue":"1","key":"916_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1749-6632.1982.tb22124.x","volume":"389","author":"I Kushner","year":"1982","unstructured":"Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982;389(1):39\u201348. https:\/\/doi.org\/10.1111\/j.1749-6632.1982.tb22124.x.","journal-title":"Ann N Y Acad Sci"},{"key":"916_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00754","author":"NR Sproston","year":"2018","unstructured":"Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.00754.","journal-title":"Front Immunol"},{"issue":"4","key":"916_CR36","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/pharmaceutics3040865","volume":"3","author":"MS Bolhuis","year":"2011","unstructured":"Bolhuis MS, Panday PN, Pranger AD, Kosterink JGW, Alffenaar J-WC. Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams. Pharmaceutics. 2011;3(4):865\u2013913. https:\/\/doi.org\/10.3390\/pharmaceutics3040865.","journal-title":"Pharmaceutics"},{"issue":"10","key":"916_CR37","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1124\/dmd.112.046748","volume":"40","author":"J Sugatani","year":"2012","unstructured":"Sugatani J, Uchida T, Kurosawa M, Yamaguchi M, Yamazaki Y, Ikari A, et al. Regulation of pregnane X receptor (PXR) function and UGT1A1 gene expression by posttranslational modification of PXR protein. Drug Metab Dispos. 2012;40(10):2031\u201340. https:\/\/doi.org\/10.1124\/dmd.112.046748.","journal-title":"Drug Metab Dispos"},{"key":"916_CR38","doi-asserted-by":"publisher","unstructured":"Cross-sectional guidelines for therapy with blood components and plasma derivatives (4th revised edition, 2008) \u2013 suspension of chapter 5 \u2018human albumin.\u2019 Transfus Med Hemother. 2011;38(1):71\u201371. https:\/\/doi.org\/10.1159\/000324247","DOI":"10.1159\/000324247"},{"issue":"7","key":"916_CR39","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/bcp.13595","volume":"84","author":"X-B Lin","year":"2018","unstructured":"Lin X-B, Li Z-W, Yan M, Zhang B-K, Liang W, Wang F, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol. 2018;84(7):1587\u201397. https:\/\/doi.org\/10.1111\/bcp.13595.","journal-title":"Br J Clin Pharmacol"},{"key":"916_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01211-17","author":"Z Hashemizadeh","year":"2017","unstructured":"Hashemizadeh Z, Badiee P, Malekhoseini SA, Raeisi Shahraki H, Geramizadeh B, Montaseri H. Observational study of associations between voriconazole therapeutic drug monitoring, toxicity, and outcome in liver transplant patients. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.01211-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"916_CR41","doi-asserted-by":"publisher","unstructured":"Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ. 2006;333(7577):1044. https:\/\/doi.org\/10.1136\/bmj.38985.398704.7c","DOI":"10.1136\/bmj.38985.398704.7c"},{"issue":"8","key":"916_CR42","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1128\/aac.46.8.2546-2553.2002","volume":"46","author":"L Purkins","year":"2002","unstructured":"Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546\u201353. https:\/\/doi.org\/10.1128\/aac.46.8.2546-2553.2002.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"916_CR43","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1128\/aac.00949-10","volume":"55","author":"S Weiler","year":"2011","unstructured":"Weiler S, Fiegl D, MacFarland R, Stienecke E, Bellmann-Weiler R, Dunzendorfer S, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother. 2011;55(2):925\u20138. https:\/\/doi.org\/10.1128\/aac.00949-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"916_CR44","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1128\/aac.03252-14","volume":"58","author":"O Blennow","year":"2014","unstructured":"Blennow O, Eliasson E, Pettersson T, Pohanka A, Szakos A, El-Serafi I, et al. Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2014;58(8):4941\u20133. https:\/\/doi.org\/10.1128\/aac.03252-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"916_CR45","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1365-2125.2012.04422.x","volume":"75","author":"A Haouala","year":"2013","unstructured":"Haouala A, Widmer N, Guidi M, Montemurro M, Leyvraz S, Buclin T, et al. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. Br J Clin Pharmacol. 2013;75(4):1007\u201318. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04422.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"916_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1124\/dmd.110.035105","volume":"39","author":"SJ Shukla","year":"2011","unstructured":"Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, VanLeer D, et al. Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos. 2011;39(1):151\u20139. https:\/\/doi.org\/10.1124\/dmd.110.035105.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"916_CR47","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1128\/aac.00423-11","volume":"55","author":"B Damle","year":"2011","unstructured":"Damle B, Varma MV, Wood N. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob Agents Chemother. 2011;55(11):5172\u20137. https:\/\/doi.org\/10.1128\/aac.00423-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"916_CR48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13318-023-00852-6","volume":"48","author":"F Liu","year":"2023","unstructured":"Liu F, Aulin LBS, Manson ML, Krekels EHJ, van Hasselt JGC. Unraveling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal glomerular filtration rate and cytochrome P450 3A4-mediated metabolism. Eur J Drug Metab Pharmacokinet. 2023;48(6):623\u201331. https:\/\/doi.org\/10.1007\/s13318-023-00852-6.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"916_CR49","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13318-023-00859-z","volume":"48","author":"X Chen","year":"2023","unstructured":"Chen X, Yu G, Li G-F. Use of clearance concepts to simulate impact of interleukin-6 on drug elimination governed by cytochromes P450 3A4 and glomerular filtration rate. Eur J Drug Metab Pharmacokinet. 2023;48(6):619\u201321. https:\/\/doi.org\/10.1007\/s13318-023-00859-z.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"21","key":"916_CR50","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"J-L Vincent","year":"2009","unstructured":"Vincent J-L. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323. https:\/\/doi.org\/10.1001\/jama.2009.1754.","journal-title":"JAMA"},{"issue":"4","key":"916_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1081\/clt-58950","volume":"43","author":"MC Yarema","year":"2005","unstructured":"Yarema MC, Becker CE. Key concepts in postmortem drug redistribution. Clin Toxicol (Phila). 2005;43(4):235\u201341. https:\/\/doi.org\/10.1081\/clt-58950.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"916_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12890-022-01904-4","volume":"22","author":"S Verfaillie","year":"2022","unstructured":"Verfaillie S, Godinas L, Spriet I, Vos R, Verleden GM. Interaction between posaconazole and flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole and possible undertreatment of invasive aspergillosis: case report. BMC Pulm Med. 2022;22(1):110. https:\/\/doi.org\/10.1186\/s12890-022-01904-4.","journal-title":"BMC Pulm Med"},{"issue":"6","key":"916_CR53","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/jac\/dkad107","volume":"78","author":"JM Wortman","year":"2023","unstructured":"Wortman JM, Leegwater E, Van Lammeren-Venema D, Van Nieuwkoop C, Sobels A, Wilms EB. Drug-drug interaction: decreased posaconazole trough concentrations during concomitant flucloxacillin treatment. J Antimicrob Chemother. 2023;78(6):1471\u20135. https:\/\/doi.org\/10.1093\/jac\/dkad107.","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00916-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00916-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00916-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:10:38Z","timestamp":1731071438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00916-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["916"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00916-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]},"assertion":[{"value":"18 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A non-WMO acknowledgment from the Medical Research Ethics Committee (METC) Amsterdam UMC has been authorized on July 6<sup>th<\/sup> 2023 (METC number 20230447, 156982).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The included patients gave informed consent for participation in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patients gave informed consent for the data collected for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors participated in designing and performing this study. HA, JN and IB wrote the first version of this paper, and all the authors reviewed it. IB was the leading researcher to finalize this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The authors received no financial support for the research, authorship, and\/or publication of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The data are shown in the paper and code is available in the supplements.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of code, data and material"}}]}}